Global Immunotherapy Drugs for Neuroblastoma Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Immunotherapy Drugs for Neuroblastoma Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
Immunotherapy Drugs for Neuroblastoma report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2024. Global Immunotherapy Drugs for Neuroblastoma market is projected to reach US$ 63 million in 2034, increasing from US$ 45 million in 2024, with the CAGR of 4.6% during the period of 2023 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Immunotherapy Drugs for Neuroblastoma industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2034.
Globally, Immunotherapy Drugs for Neuroblastoma key manufacturers include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma are top 3 players and held % sales share in total in 2024.
Immunotherapy Drugs for Neuroblastoma can be divided into Dinutuximab, Naxitamab and Other,, etc. Dinutuximab is the mainstream product in the market, accounting for % sales share globally in 2024.
Immunotherapy Drugs for Neuroblastoma is widely used in various fields, such as Hospital, Clinic and Other,, etc. Hospital provides greatest supports to the Immunotherapy Drugs for Neuroblastoma industry development. In 2024, global % sales of Immunotherapy Drugs for Neuroblastoma went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Immunotherapy Drugs for Neuroblastoma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Segment by Type
Dinutuximab
Naxitamab
Other
Hospital
Clinic
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Immunotherapy Drugs for Neuroblastoma market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Immunotherapy Drugs for Neuroblastoma, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Immunotherapy Drugs for Neuroblastoma industry.
Chapter 3Historical (2018-2024) and forecast (2024-2034) volume and revenue analysis of Immunotherapy Drugs for Neuroblastoma in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Immunotherapy Drugs for Neuroblastoma introduction, etc. Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Immunotherapy Drugs for Neuroblastoma market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Immunotherapy Drugs for Neuroblastoma report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2024. Global Immunotherapy Drugs for Neuroblastoma market is projected to reach US$ 63 million in 2034, increasing from US$ 45 million in 2024, with the CAGR of 4.6% during the period of 2023 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Immunotherapy Drugs for Neuroblastoma industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2034.
Globally, Immunotherapy Drugs for Neuroblastoma key manufacturers include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma are top 3 players and held % sales share in total in 2024.
Immunotherapy Drugs for Neuroblastoma can be divided into Dinutuximab, Naxitamab and Other,, etc. Dinutuximab is the mainstream product in the market, accounting for % sales share globally in 2024.
Immunotherapy Drugs for Neuroblastoma is widely used in various fields, such as Hospital, Clinic and Other,, etc. Hospital provides greatest supports to the Immunotherapy Drugs for Neuroblastoma industry development. In 2024, global % sales of Immunotherapy Drugs for Neuroblastoma went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Immunotherapy Drugs for Neuroblastoma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Segment by Type
Dinutuximab
Naxitamab
Other
Segment by Application
Hospital
Clinic
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Immunotherapy Drugs for Neuroblastoma market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Immunotherapy Drugs for Neuroblastoma, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Immunotherapy Drugs for Neuroblastoma industry.
Chapter 3Historical (2018-2024) and forecast (2024-2034) volume and revenue analysis of Immunotherapy Drugs for Neuroblastoma in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Immunotherapy Drugs for Neuroblastoma introduction, etc. Immunotherapy Drugs for Neuroblastoma Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Immunotherapy Drugs for Neuroblastoma market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices